CTLA4 and neuroblastoma: Poorly immunogenic neuroblastoma tumors that are refractory to immune checkpoint inhibitors can be sensitized to anti-CTLA4 with induced mismatch repair (MMR) deficiency leading to the establishment of broad immunological memory.